BranchLab has launched Privacy Updates for Marketing Activation, a resource providing state-by-state legal intelligence on how privacy developments affect healthcare advertising and commercialisation. The service initially covers eight US states — California, Connecticut, Illinois, Maryland, New Jersey, New York, Texas, and Washington — selected for their significance to healthcare privacy. Coverage will expand to all 50 states. The resource connects legislation, regulation, enforcement, and case law to healthcare marketing decisions. It builds on BranchLab's Semantic Activation Platform for healthcare commercialisation, where privacy and responsible data use are central features. "Privacy has become one of the defining considerations affecting healthcare commercialisation," said Josh Walsh, chief executive officer of BranchLab. The service is available at the company's website and is provided for informational purposes only.

BranchLab, an AI platform for pharmaceutical commercialisation, has raised $26 million in Series A funding led by McKesson Ventures, bringing total funding to $35 million. FCA Venture Partners, Sanofi Ventures and AIX Ventures participated in the round. The Boulder-based company replaces fragmented pharma commercialisation workflows with a unified AI platform that enables real-time patient and healthcare professional audience identification and activation. BranchLab reports its platform has delivered a nearly 70% increase in marketing efficacy across therapeutic areas for pharmaceutical clients. The platform uses a transformer-based architecture that trains models on health data within customer-controlled environments whilst deploying only non-sensitive demographic signals. BranchLab will use the funding to expand enterprise deployments and deepen healthcare ecosystem integrations.